Retraction: Combination Anti-CTLA-4 and Anti-RANKL in metastatic melanoma (Journal of Clinical Oncology (2016) DOI: 10.1200/JCO.2013.51.3572);Combination anti-CTLA-4 and Anti-RANKL in metastatic melanoma

Journal of Clinical Oncology

Volumn 32, Issue , 2014, Pages 4448-

  Smyth, Mark J ^a,b,c,d   Yagita, Hideo ^e   Mcarthur, Grant A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DENOSUMAB; FLUORODEOXYGLUCOSE; IPILIMUMAB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

ADULT; ANEMIA; ARTICLE; BONE PAIN; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; EMISSION TOMOGRAPHY; FEMALE; HUMAN; METASTATIC MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEREOTACTIC TREATMENT; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; BRAIN NEOPLASMS; GENETICS; IMMUNOLOGY; LYMPH NODE METASTASIS; MELANOMA; PATHOLOGY; PROCEDURES; SECONDARY; SKIN NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; WHOLE BODY IMAGING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; CTLA-4 ANTIGEN; DENOSUMAB; FEMALE; HUMANS; LYMPHATIC METASTASIS; MELANOMA; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; RANK LIGAND; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84985991765     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.23.01358     Document Type: Erratum

References (10)

1. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736, 1996.
2. Teng MW, Ngiow SF, von Scheidt B, et al: Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 70:7800-7809, 2010.
3. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010.
4. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011.
5. Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717-1725, 2009.
6. Byrne WL, Mills KH, Lederer JA, et al: Targeting regulatory T cells in cancer. Cancer Res 71:6915-6920, 2011.
7. Body JJ, Lipton A, Gralow J, et al: Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 25:440-446, 2010.
8. Fizazi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571, 2009.
9. Tan W, Zhang W, Strasner A, et al: Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548-553, 2011.
10. Zaiss MM, Axmann R, Zwerina J, et al: Treg cells suppress osteoclast formation: A new link between the immune system and bone. Arthritis Rheum 56:4104-4112, 2007.